U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT06880419) titled 'Anti-CD25 rhMAb for aGVHD Prevention in High-Risk Adults Using the daGOAT Model' on March 11.
Brief Summary: To assess the efficacy and safety of using recombinant humanized anti-CD25 monoclonal antibody injection as a prophylactic strategy for reducing the incidence of severe acute graft-versus-host disease (aGVHD) in adult patients at intermediate to high risk, as predicted by the dynamic aGVHD Onset Anticipation Tianjin (daGOAT) model, following allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Acute Graft-versus-Host Disease
Intervention:
DR...